The Trigeminal Neuralgia (Tic Douloureux) drugs in development market research report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Tic Douloureux), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Trigeminal Neuralgia (Tic Douloureux). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued products.

GlobalData tracks 15 drugs in development for Trigeminal Neuralgia (Tic Douloureux) by 15 companies/universities/institutes. The top development phase for Trigeminal Neuralgia (Tic Douloureux) is preclinical with seven drugs in that stage. The Trigeminal Neuralgia (Tic Douloureux) pipeline has 13 drugs in development by companies and two by universities/ institutes. Some of the companies in the Trigeminal Neuralgia (Tic Douloureux) pipeline products market are: Amgen, InMed Pharmaceuticals and University of Wisconsin-Milwaukee.

The key targets in the Trigeminal Neuralgia (Tic Douloureux) pipeline products market include Peroxisome Proliferator Activated Receptor Gamma (Nuclear Receptor Subfamily 1 Group C Member 3 or NR1C3 or PPARG), Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5), and Transient Receptor Potential Cation Channel Subfamily V Member 4 (Osm 9 Like TRP Channel 4 or Vanilloid Receptor Like Protein 2 or TRPV4).

The key mechanisms of action in the Trigeminal Neuralgia (Tic Douloureux) pipeline product include Peroxisome Proliferator Activated Receptor Gamma (Nuclear Receptor Subfamily 1 Group C Member 3 or NR1C3 or PPARG) Agonist with one drug in Preclinical. The Trigeminal Neuralgia (Tic Douloureux) pipeline products include 11 routes of administration with the top ROA being Intravenous and seven key molecule types in the Trigeminal Neuralgia (Tic Douloureux) pipeline products market including Small Molecule, and Antisense Oligonucleotide.

Trigeminal Neuralgia (Tic Douloureux) overview

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from the face to the brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking, and brushing teeth; pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

For a complete picture of Trigeminal Neuralgia (Tic Douloureux)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.